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Abstract
Maintaining sufficient levels of Pdx1 activity is a prerequisite for proper regulation of blood glucose homeostasis and beta
cell function. Mice that are haploinsufficient for Pdx1 display impaired glucose tolerance and lack the ability to increase beta
cell mass in response to decreased insulin signaling. Several studies have shown that post-translational modifications are
regulating Pdx1 activity through intracellular localization and binding to co-factors. Understanding the signaling cues
converging on Pdx1 and modulating its activity is therefore an attractive approach in diabetes treatment. We employed a
novel technique called Nanofluidic Proteomic Immunoassay to characterize the post-translational profile of Pdx1. Following
isoelectric focusing in nano-capillaries, this technology relies on a pan specific antibody for detection and it therefore allows
the relative abundance of differently charged protein species to be examined simultaneously. In all eukaryotic cells tested
we find that the Pdx1 protein separates into four distinct peaks whereas Pdx1 protein from bacteria only produces one
peak. Of the four peaks in eukaryotic cells we correlate one of them to a phosphorylation Using alanine scanning and mass
spectrometry we map this phosphorylation to serine 61 in both Min6 cells and in exogenous Pdx1 over-expressed in
HEK293 cells. A single phosphorylation is also present in cultured islets but it remains unaffected by changes in glucose
levels. It is present during embryogenesis but is not required for pancreas development.
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Introduction
Pancreatic and duodenal homeobox 1 (Pdx1) also known as Ipf1 and
Stf1 is a master regulator of pancreas development [1,2,3]. Pdx1
was first cloned and described in Xenopus,a sXlhbox8, where it was
shown to be expressed in the developing endoderm and pancreas
[4]. In mouse embryos Pdx1 is expressed in the endoderm from
e8.5 where it defines the regions that will form the dorsal and
ventral pancreas [1,2,5]. The evidence that Pdx1 is instrumental
for pancreas development comes from both mouse and human
where depletion of a functional Pdx1 protein results in pancreas
agenesis [1,2,6]. Conversely, over expression of Pdx1 in endoder-
mal cells outside the presumptive pancreas can activate events
reminiscent of pancreas development. In chicken embryos forced
expression of Pdx1 in the developing endoderm partially induces
pancreas development. Thus, ectopic Pdx1 quenches the expres-
sion of non-pancreatic genes such as Sox2 and Cdx in regions
outside the presumptive pancreas [7] while it induces pancreatic
markers like Nkx6.1 [8]. In Xenopus, over expression of a modified
Pdx1, carrying the VP16 transcriptional activation domain can
cause conversion of liver to pancreas [9].
Postnatally Pdx1 is expressed in the mature b-cell where it
serves as an important regulator of glucose homeostasis [10,11].
In humans, mutations in the Pdx1 gene have been associated
with type 2 diabetes and maturity onset diabetes of the young 4
(MODY4) [12,13]. This role is conserved in evolution and
impaired glucose tolerance has been observed in several animal
models where Pdx1 protein levels have been depleted or
reduced [10,14,15,16,17,18]. Furthermore, the diabetic pheno-
type observed following Pdx1 inactivation is reversible and
blood glucose levels can be normalized if Pdx1 expression is
reactivated [19]. In the sand rat (Psammonys obesus) which
normally lacks Pdx1 in the b-cells, reintroduction of the protein
greatly improves glucose stimulated insulin transcription [15].
Several studies have shown that Pdx1 directly influences glucose
homeostasis by binding and regulating the promoters of genes
such as insulin (ins), glut2 (Slc2a2) and glucokinase (Gck)
[3,20,21,22]. However, in addition to the immediate effects of
Pdx1 on glucose homeostasis studies in mice haploinsufficient
for Pdx1 have revealed a long term requirement for correct
Pdx1 dosage. In the mature b-cell the loss of one Pdx1 allele
affects both glucose stimulated insulin release and b-cell survival
[11]. Furthermore, the compensatory increase in b-cell mass
associated with impaired insulin signaling relies on Pdx1 dosage.
Mice that are double heterozygous for mutations in the insulin
receptor (Ir) and the insulin receptor substrate (Irs) display impaired
insulin signaling and respond by increasing their the b-cell mass.
This expansion is abolished in mice that are haploinsufficient
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levels has such deteriorating effects on the b-cell, however, a
recent study suggests that it may be linked to mitochondrial
dysfunction. Thus preventing opening of the mitochondrial
permeability transition pore through deletion of the Peptidyl-prolyl
cis-trans isomerase (Ppif) gene restores many of the defects caused
by Pdx1 insufficiency [24].
Since even subtle changes in Pdx1 levels dramatically impacts
b-cell performance it is generally acknowledged that the biological
activity of Pdx1 tightly regulated at the post-translational level.
Fitting this hypothesis at least three different post-translational
modifications have been reported on Pdx1 including phosphoryla-
tion [25,26,27,28,29,30,31,32,33,34,35], glycosylation [36] and
sumoylation[37].Phosphorylation,inparticular,hasbeenshownto
regulate several important aspects of Pdx1 activity in response to
elevated glucose levels, such as nuclear-cytoplasmic shuttling
[26,27], DNA binding [27,28,38] and interactions with transcrip-
tional co-factors [25,39]. Several different kinases have been shown
to phosphorylate Pdx1 and to date five different residues have been
suggested to be Pdx1 kinase substrates. Amino acids S61 or S66 are
phosphorylatedbyGlycogensynthasekinase3(Gsk3)and ERK1/2
[29,31] and this modification targets Pdx1 for proteasomal
degradation in response to oxidative stress [29]. Amino acids S268
and S272 (S269 and S273 in mouse) are phosphorylated by Hipk2
[40]orinresponsetolowglucose[30]andT11isphosphorylatedby
DNA-dependent kinase in response to DNA damage [33]. Yet,
despite the attention several important questions remain unan-
swered. For example it is unclear to what extent Pdx1 is modified
under normal conditions? How many PTMs are present at a given
time? How do different PTMs influence each other? How is the
endogenous Pdx1 modified in respond to various treatments?
Here we have employed a novel technique called nanofluidic
proteomic immunoassay (NIA) [41,42] to study post-translation-
al modifications of Pdx1 in various cell types. NIA employs
isoelectric focusing to separate differently charged protein
species of the same protein which is then detected using a
pan-specific antibody. A particular advantage of this technology
is that experiments can be carried out from scarce samples [42].
We have therefore been able to identify and study different
protein species of endogenous Pdx1 in cell lines, during
development and in mature b-cells. In eukaryotic cells we
observe that the Pdx1 protein separates into four peaks, while
Pdx1 purified from bacteria only produces a single peak. There
is no apparent difference in SDS-PAGE mobility between
mammalian and bacterial Pdx1 proteins and we therefore
conclude that the mammalian profile is the result of post-
translational modifications. Treating the Pdx1 protein with
phosphatase revealed the presence of one primary phosphory-
lation which was mapped to serine 61 using both alanine
scanning and mass spectrometry. Remarkably, Pdx1 protein
obtained from, embryonic tissue, adult pancreas, isolated islets,
bTC cells, Min6 cells and from Pdx1 over-expressed in aTC, L
and HEK293 cells produces almost identical profiles. Since the
single phosphorylation is present in all cells and tissues tested we
speculate that it is mediated by a ubiquitously expressed kinase
rather than a specific signaling pathway. In line with this we
were unable to demonstrate any alterations in the Pdx1 profile
following high or low glucose treatment of mouse islets in
culture. And although we confirm that Pdx1 is phosphorylated
during embryonic pancreas development, we find that Pdx1
S61A
is fully capable of inducing ectopic Nkx6.1 expression and
budding of pancreatic like structures.
Results
Over Expressed Pdx1 Appear as Multiple Protein Species
To investigate the extent of post-translational modifications on
the endogenous Pdx1 protein we applied a novel technology called
NIA [41,42]. Isoelectric focusing is used to separate differently
charged species of a protein which subsequently can be detected
using a pan-specific antibody that recognizes these species with
similar affinity (assuming equal antibody binding to the different
protein species). The raw data can be examined as bands on a gel
or as peaks (Fig. 1A) where the relative abundance of the different
protein species can be estimated from the height of the peaks or as
the area under the curves (Fig. 1B). To precisely determine which
peaks can be assigned to Pdx1 we performed western blot and NIA
analysis on lysates from cells over-expressing wild type mouse
Pdx1 (Pdx1
WT), using two different antibodies against Pdx1. A
polyclonal goat-a-Pdx1 antibody and a monoclonal mouse-a-Pdx1
antibody [43]. When used for western we found that both
antibodies specifically detected a 40 kDa band in cells transfected
with Pdx1
WT (Fig. 1C). When the same lysates was used for NIA
the empty vector control displayed no peaks whereas both
antibodies produced peaks at pI 5.9, 6.0, 6.1, 6.3 and 6.4 in
Pdx1 transfected cells (Fig. 1D and E). The only difference was the
5.8 peak which is absent when using the mouse antibody.
Pdx1 is Subject to Post-translational Modification in
Mammalian Cells
To test if the antibodies specifically recognize various protein
species of Pdx1 the entire profile should be shifted if the overall pI
is changed. We therefore added a negatively charged 3xFLAG
epitope tag to the C-terminus of wild type Pdx1 (Pdx1
3xFLAG). This
changes the predicted pI of Pdx1 from 6.4 for the wild type to 5.5
for the 3xFLAG tagged Pdx1. The increase in size was confirmed
on a western blot (Fig. 2A) and as predicted the NIA profile of
FLAG tagged Pdx1 was shifted to the left (Fig. 2B; red line).
Importantly, all peaks are shifted to the left indicating that the
added FLAG tag affects all Pdx1 protein species. It should be
noted that the leftward shift of the profile is associated with a
compression of the NIA profile, leading to the 6.0 and 6.1 as well
as the 6.3 and 6.4 peaks becoming indistinguishable. However, to
confirm that Pdx1 is actually modified we went on to purify Pdx1
from either bacteria or mammalian cells and analyzed the purified
proteins using SDS-PAGE and NIA. The cDNA encoding wild
type Pdx1 was cloned into two vectors which allowed expression in
either bacteria or mammalian cells, respectively. Pdx1 protein was
subsequently purified using the mouse-a-Pdx1 antibody for
immunoprecipitation (IP) and then the goat-a-Pdx1 antibody for
western and NIA. On SDS-PAGE the purified protein migrated at
approximately 40 kDa and could be detected by western from
both bacteria and HEK293 cells while control samples where
negative (Fig. 2C). When the same samples were analyzed on NIA
bacterial Pdx1 gave a single peak at pI 7.2 (Fig. 2D) while the
profile obtained from mammalian Pdx1 was similar to that
obtained without IP and the most prominent peaks were detected
at pI 5.9, 6.0, 6.1, 6.4 but we also observed lower intensity peaks at
pI 5.6, 6.5, 6.9 and 7.2 (Fig. 2E). To further validate these results
we repeated the experiment using the Pdx1
3xFLAG construct.
When this approach was used to purify protein from bacteria we
detected some unspecific bands both using coomassie and western
blotting (Fig. 2F), importantly, the Pdx1
3xFLAG band was the
strongest signal in the lane and the controls were blank. NIA
analysis of Pdx1
3xFLAG obtained from bacteria revealed one Pdx1
specific peak at pI 5.9, while a smaller 5.6 peak was present in both
Pdx1 and control lysates (Fig. 2G). We therefore believe that the
Post-Translational Modification of Pdx1
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3xFLAG protein. NIA analysis of Pdx1
3xFLAG
purified from HEK cells resulted in four specific peaks at 5.1, 5.2,
5.3 and 5.5 which are similar to those observed when analyzing
the lysates without the IP step (Fig. 2H). As for IP of Pdx1
WT,
lower intensity bands is also evident for Pdx1
3xFLAG and we believe
that the peaks at pI 5.8 and 5.9 corresponds to the 6.9 and 7.2
peaks found for Pdx1
WT. In contrast the 5.6 peak is found in both
control and Pdx1 expressing cells and this peak does not move in
the response to the 3xFLAG tag, indicating that it is unspecific
binding of the goat-a-Pdx1 antibody.
Lastly, to rule out that differences in buffer composition
following the IP could influence the migration of Pdx1 in the
nano capillaries we carried out a series of experiments where the
purified Pdx1 from bacteria or mammalian cells where spiked
directly into lysates from HEK cells transfected with EGFP or
Pdx1
3xFLAG (Fig. S1). These results strongly indicate that the
bacterial Pdx1 generates one single peak with a pI that is different
from the Pdx1 expressed in mammalian cells, thus confirming the
presence of post-translational modifications on Pdx1 when
expressed in mammalian cells.
Endogenous Pdx1 also Exist in Multiple Isoforms
Having confirmed that we are able to detect multiple
isoforms of Pdx1 following over-expression in mammalian cell
lines we went on to test if the NIA analysis could be used to
detect endogenous Pdx1 protein. We therefore analyzed the
Pdx1 profile from various cell types and tissues known to be
positive or negative for Pdx1 expression. Another question we
wanted to address was to what extent the Pdx1 profile is
influenced by protein-protein interactions. Normally, the NIA
analysis is conducted in a mild Hepes buffer (HNG) and it is
therefore possible that some of the Pdx1 peaks we observe
represent a protein complex. We therefore compared the
profiles of endogenous Pdx1 in the HNG buffer (Fig. 3A-D)
with that obtained in 8 M urea which will denature most
interactions (Fig. 3A’-D’). According to the manufactures
instruction urea treatment gives better resolution but reduces
signal intensity. Using the goat-a-Pdx1 antibody on bTC cells
the characteristic 6.0, 6.1 and 6.4 peaks were clearly seen in
both buffers (Fig. 3A, 3A’). To a lesser extend also the 5.9 peak
and perhaps the 6.3 as a faint shoulder on the left side foot of
the 6.4 peak. The 6.9 peak was small but significantly present in
HNG buffer only, whereas the 6.5 peak was only observed in
the urea treated samples. The peak at 5.8 which was only
detected with the goat-a-Pdx1 antibody was present in both
buffers while the non-pdx1 peak at 5.6 was only observed with
urea. In aTC cells which express little or no Pdx1, the strongest
peaks were at pI 5.5 and 5.6 and perhaps also at 6.5 in urea
treated lysate (Fig. 3B, 3B’). In embryonic tissue Pdx1 is
expressed in the pancreatic endoderm and in three independent
lysates from isolated embryonic pancreata we observed a profile
very similar to bTC with the strongest peaks at pI 6.0, 6.1 and
6.4 (Fig. 3C, 3C’). This observation was very reproducible in
both buffers although again the peaks around 5.6 became more
prominent in 8M urea. Lastly, we compared the profile
obtained from three independent samples of isolated mouse
islets (Fig. 3D, 3D’). Here we observed increased variation
between the different samples, but interestingly in the urea
treatment revealed a strong peak at pI 6.9 in addition to the
characteristic 6.0 and 6.4 peaks. We also detected some smaller
peaks around 5.9, 6.1 and 6.8. Lastly, we analyzed the different
Figure 1. Over expression of Pdx1 in L and HEK293 cells. A) Raw data from the NIA analysis can be visualized as gel-bands or as a graph. B)
The intensity of the signal can be estimated based on the height of the peak or the area under the curve. C-E) Over expression of empty vector or
pdx1
WT in L cells followed by western blotting using a goat-a-Pdx1 (C, top) or a mouse-a-Pdx1 antibody (C, bottom) and NIA analysis of the same
lysates using the goat-a-Pdx1 (D) or mouse-a-Pdx1 antibody (E).
doi:10.1371/journal.pone.0035233.g001
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the peaks at 6.0, 6.1 and 6.4 as well as the islet enriched 6.9
peak.
In summary the NIA analysis of three cell types known to
express endogenous Pdx1 produced several peaks which varied
slightly between the different cell types. However, the overall
profile is very similar to that obtained using over-expression.
Both Endogenous and Exogenous Pdx1 Carry One
Principal Phosphorylation
Dependingonexpressionlevelsandcelltypeswedetectatleastfour
orfivedifferentiallychargedisoformsofPdx1invariouscelltypesand
tissueswhilebacteriallygeneratedPdx1onlyproducesasinglepeak.
This strongly suggests that Pdx1 is subject to post translational
modifications in mammalian cells. Numerous studies have shown
thatPdx1isphosphorylated[25,26,27,28,29,30,31,32,33,34]andto
Figure 2. The Pdx1 NIA profile differs between bacterial and mammalian cells. First, a comparison of the basal NIA profile of pdx1
WT and
pdx1
3xFLAG protein from transfected HEK293 cells by western blotting (A) and NIA (B), employing the goat-a-Pdx1 antibody. The amino acids in the
3xFLAG tag are negatively charged and in agreement a left shift of the NIA profile is observed. Results are representative of at least three
independent experiments. Then a comparison of purified Pdx1
WT and Pdx1
3xFLAG protein from E.Coli BL21 cells versus purified protein from HEK293
cells. Plasmids coding for the indicated proteins were expressed in BL21or HEK293 cells and purified by immunoprecipitation using a monoclonal
mouse-a-Pdx1 antibody coupled to protein G beads (Pdx1
WT) or with anti-FLAG beads (Pdx1
3xFLAG). As negative control cell lysate from non
transformed bacteria or empty vector (EV) transfected HEK293 cells were ran in parallel. Purified protein from Pdx1
WT expressing and non expressing
BL21 and HEK293 cells were analyzed by coomassie staining and western blot (C) and by NIA, (D) BL21, (E) HEK293. F-H) Similar analysis for
Pdx1
3xFLAG. These experiments were performed at least twice obtaining similar results.
doi:10.1371/journal.pone.0035233.g002
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aTC cells which express little or no Pdx1. To rule out the possibility of protein-protein complexes affecting the NIA profile, the lysates were diluted 20
fold in a mild Hepes buffer (HNG) (A-D) or in 8 M urea (A’-D’) prior to NIA analysis. Using the goat-a-Pdx1 antibody, the characteristic 6.0, 6.1 and 6.4
peaks and to a lesser extend also the 6.3 peak is observed in bTC (A, A’) but not in aTC (B, B’). To show the reproducibility of the NIA assay between
the HNG and 8 M urea we compared the Pdx1 profile from e15.5 mouse pancreas obtained from three different litters (C, C’) and from 3 different
preparations of purified mouse islets (D, D’). We also performed these analyses with the mouse-a-Pdx1 antibody (Fig. S2), confirming the dominant
peaks at 6.0, 6.1 and 6.4 as well as the islet enriched 6.9 peak.
doi:10.1371/journal.pone.0035233.g003
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subsequently incubated with or without Lambda phosphatase and
subjected to NIA analysis. The NIA profile from non-treated and
phosphatasetreatedlysatesweresuperimposedandrevealedthatthe
phosphatasetreatmentshiftedthe6.0peakto6.1whilethe6.3and6.4
peaksremainedunaffected(Fig.4A).ThissuggeststhatPdx1harbors
one primary phosphorylation represented by the 6.0 peak. The
smaller peaks at 5.9 are also affected by the phosphatase treatment
and it is likely that they represent additional but less abundant
phosphorylations. To validate that the phosphatase treatment per se
did not affect the NIA profile we analyzed the same lysates for the
endogenousproteinHsp70(Fig.4B)andfoundtheHsp70profilesfor
treated verses non-treated to be identical. Similar results were
observed in bTC (Fig. 4C) and mouse islets (Fig. 4D) which express
endogenous Pdx1.
Serine 61 is the Primary Site of Phosphorylation in Pdx1
To test if the NIA assay could be used to map the
phosphorylated residue in Pdx1 we carried out an alanine scan
where all serines, tyrosines and threonines which are putative
phosphorylation sites were replaced by alanine. Plasmids encoding
the mutated Pdx1 proteins were transfected into L cells and aTC
cells. The lysates were analyzed using NIA or western blots to
confirm the expression and SDS-PAGE mobility of Pdx1 (Fig. 5A).
To estimate the amount of phosphorylated Pdx1 we took
advantage of the observation that the signal intensity of the 6.4
peak is unaffected by phosphorylation while the intensity of the 6.0
peak is related to the amount of phosphorylated protein. The ratio
between the 6.4 and the 6.0 peak should therefore reflect the
relative proportion of phosphorylated Pdx1. We find that only
Pdx1
S61A differs markedly from wild type Pdx1 (Fig. 5B) and
superimposing the profile of Pdx1
S61A onto the wild type profile
revealed a marked reduction of the 6.0 peak (Fig. 5C). However, a
residual 6.0 peak which could be removed by phosphatase
treatment could still be detected, indicating the presence of at
least one additional phosphorylation (Fig. 5D). To examine how
constitutive phosphorylation affects the NIA profile of Pdx1 we
replaced serine 61 with the negatively charged residue glutamic
acid (Pdx1
S61E), hereby mimicking a phosphorylation. When
Pdx1
S61E was analyzed using the NIA assay we only observed a
single peak at pI 6.1(Fig. 5E) suggesting that the modifications of
Pdx1 are absent if the protein is phosphorylated. This might also
explain why the 6.3 and 6.4 peaks are unaffected following de-
phosphorylation.
Mass Spectrometry Analysis of Pdx1
The NIA analysis of Pdx1 identified S61 as the primary
phosphorylation of Pdx1 in L cells, aTC cells and HEK293
cells (data not shown). To confirm this finding we purified Pdx1
protein from over-expressing HEK293 cells or from Min6 cells
which express endogenous Pdx1. The purified protein was
initially digested with trypsin. However, despite a 98% coverage
of the Pdx1 protein, we were not able to conclusively detect the
S61 phosphorylation. In order to investigate this discrepancy in
Figure 4. Pdx1 is phosphorylated. In order to determine the identity of the peaks found in the Pdx1 profile we treated the lysate with lambda
phosphatase to see if the removal of phosphorylations would shift the peaks. A-D) NIA profile (in 8 M urea) of the dephosphorylated lysate (red) is
show superimposed on the control treated lysate (grey). A) Over expression of pdx1
WT in L results in a shift of the 6.0 peak to 6.1, which fits the
expected change in pI caused by a phosphorylation. The 6.40 peak is unaffected by the dephosphorylation. B) The NIA profile of Hsp70 from the
same lysates serves as a control to show that the dephosphorylation assay does not impact the profile of a non phosphorylated protein. Control
treatment or dephosphorylation of bTC cells (C) and mouse islets (D), show similar results. Results are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0035233.g004
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prior to mass spectrometric analysis. Using chymotrypsin
ensures that Pdx1 is proteolytically cleaved at different amino
acids (Phe, Ile, Tyr and Trp) as compared to when using
trypsin (Lys and Arg). This allows for increased sequence
coverage of the analyzed protein and hence increased analytical
coverage of PTMs. Using this strategy we were able to
significantly confirm the presence of S61 phosphorylation in
both HEK293 cells (Fig. 6A) and in Min6 cells (Fig. 6B). To
evaluate the occupancy rate for the identified phosphorylation
sites we compared the peptide abundance of unmodified peptide
to its phosphorylated counterpart (Fig 6C). Although this is not
the most accurate measure it still provides information as to
how extensive a given amino acid is phosphorylated. The
comparison reveals that S61 indeed is the most highly abundant
phosphorylation form in comparison to S269, with a ,12% S61
occupancy rate in HEK293 and a corresponding S61
occupancy rate of ,5% in Min6 cells. In comparison the
occupancy rates for S269 phosphorylation in both HEK293 and
Min6 were found to be less than 1%.
The Pdx1 Profile is Remarkably Stable
Several studies have shown that Pdx1 is modified in response to
glucose stimulation and oxidative stress [26,27,28,29]. To test if the
endogenous Pdx1 profile is dependent on cellular context or
exogenous stimulation we proceeded to investigate the NIA profile
of several sources of b-cells. In the embryonic pancreas the
developing b-cells can be distinguished from other Pdx1 expressing
Figure 5. NIA profiles of Pdx1 alanine scanning shows Pdx1 to primarily be phosphorylated on serine 61. To identify putative
phosphorylation sites in Pdx1, which may not have been picked up by the MS, we carried out an alanine scan. A) All serines, tyrosines and threonines
in Pdx1 were mutated into alanines and transfected into L cells and aTC cells which are negative for endogenous Pdx1 expression and subjected to
NIA analysis. B) Western blots against Pdx1 and b-Actin were used to confirm the expression of Pdx1 from the plasmids. Since the 6.4 peak is
unaffected by dephosphorylation we used the area under curve (pI 6.4)/area under curve (pI 6.0) ratio to identify mutants where the phosphorylation
was reduced. In most cases the intensity of the two bands are similar resulting in a relative ratio around 1 in both L cells (light grey bars) and aTC cells
(dark grey bars). However, in Pdx1
S61A the phosphorylated band (pI 6.0) was reduced and as a result the relative ratio increased to around 4. The
screen was performed twice in each cell line and a representative result is shown. C-D) NIA profiles of S61 mutants (red) superimposed on the wild
type Pdx1 profile (grey) (C). Also, dephosphorylation of the S61A mutant (red) superimposed on the control-treated lysate (grey), shows a residual
peak at 6.0 which is removed by phosphatase (D).Mutating S61 to the phospho-mimic glutamic acid (E) clearly reduces the 6.0 peak. Note, that the
entire Pdx1 profile of this mutant including the 6.3 and 6.4 peaks are moved to the left, as would be expected from the calculated pI change of an
alanine to glutamic acid substitution. The NIA analysis in C-E were done in both L and aTC (data not shown) cells in least three independently
transfected cell lysates, yielding similar results.
doi:10.1371/journal.pone.0035233.g005
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arrows). In mice lacking the pro-endocrine gene Neurog3 the
endocrine lineage is absent and as a result the high expressing Pdx1
cells are no longer be detected (Fig. 7B). To test if the Pdx1 profile
fromthehighexpressingb-ellpopulationhasanyuniquefeatureswe
dissected and homogenized whole pancreata from wild type and
Neurog3 deficient e15.5 embryos and subjected the lysates to NIA
analysis. As for all other cell types analyzed we detected the 6.0, 6.1
and 6.4 peaks and we could not detect any obvious differences
between the wild type and the pancreata lacking b-cells (Fig. 7A’,
7B’). Next we examined the NIA profile from pancreas lysates of
newborn (Fig. 7C) and adult (Fig. 7D) mice pancreata to see if any
changes could be associated with the b-cells becoming functional
and being exposed to fluctuating blood glucose levels. At both P2
and in adult mice the 6.0, 6.1 and 6.4 peaks were indistinguishable
from the previously observed Pdx1 profiles including embryonic
tissue suggesting that the Pdx1 profile is relatively stable after birth.
To test if changes in glucose levels had any effect on the NIA profile
we isolated mouse islets and incubated them at low or high glucose
(2 mM and 30 mM) for 1 hour, before harvest. We confirmed that
theisletswereglucoseresponsivebymeasuringtheamountofinsulin
released to the media using western blotting (Fig. 7E). However, the
NIAanalysisshowstheprofilesfromthreeindependentexperiments
in 2 mM or 30 mM glucose, respectively (Fig. 7F, 7G). It is evident
that the profiles obtained from high and low glucose is remarkably
similar and when the ratio between the 6.0 peak and the 6.1 peak is
calculated there is no difference between the two conditions
(Fig. 7H).
Mouse Pdx1 is Modified in the Developing Endoderm of
Mouse and Chicken Embryos
In addition to its role in the b-cell Pdx1 is also required for
pancreas development during embryogenesis. At e10.5 Pdx1 is
expressed in both the dorsal and ventral pancreatic buds, in the
duodenum and in the posterior stomach (Fig. S3A). The stomach
and pancreas region from wild type embryos was micro dissected
and the pooled pancreata from two litters were analyzed by NIA
(Fig. S3A’). The signal obtained is weak but we could robustly
Figure 6. MS analysis identifies serine 61 as the principal phosphorylation site in Pdx1. To substantiate the NIA data we did mass
spectometry to identify modified residues especially looking for phosphorylations. We analyzed endogenous Pdx1 protein from Min6 cells and over
expressed Pdx1 from HEK293 cells. The mouse wildtype Pdx1 protein was, purified by immunoprecipitation using the mouse-a-Pdx1 antibody, then
separated by SDS-PAGE, digested with chymotrypsin and subjected to MS analysis. A-B) MS/MS data showing phosphorylation on wildtype Pdx1 at
serine 61 when over experessed and purified from HEK293 cells (A) or from Min6 cells (B). We then did a quantification of the amount of
phosphorylated versus non-phosphorylated Pdx1 peptides counted by the MS instrument. C) Relative amount of phosphorylated serine 61 and
serine 269 in HEK293 and Min6 cells. The MS analysis was done once.
doi:10.1371/journal.pone.0035233.g006
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during the earliest stages of pancreas development. Slightly later in
development at e12.5 the pancreas express high levels of Pdx1
while low Pdx1 expression can be detected in the stomach and
duodenum (Fig. S3B). Again we found the distinctive Pdx1 profile
albeit at higher levels (Fig. S3B’). To test if the phosphorylated
form of Pdx1 is important for pancreas development we
electroporated mouse Pdx1 into the endoderm of living chicken
embryos using in ovo electroporation [44]. Using this system Pdx1
would be expressed in an environment closely resembling the
developing pancreas and presumably be exposed to the similar
signaling cues. One day after electroporation GFP expression can
be detected throughout the endoderm (Fig. 8A). The embryos
were then dissociated into single cells and sorted into GFP negative
and GFP positive fractions using FACS. On average GFP cells
constituted 0.3% of the total number of cells (pre-sort) and 53%
after sorting. Each embryo contained 5000–10000 GFP express-
ing cells. Running NIA analysis on cells from embryos electropo-
rated only with GFP, the GFP sorted fraction was positive for GFP
but not Pdx1 (Fig. 8B), showing that we do not detect endogenous
chicken Pdx1. In the NIA analysis of embryos co-electroporated
with GFP and Pdx1 neither of the two proteins were detected in
the GFP negative fraction (Fig. 8C), but only in the GFP positive
fraction (Fig. 8D). As expected, the Pdx1 profile produced peaks at
pI 6.0 and pI 6.4 confirming that Pdx1 becomes phosphorylated in
the developing endoderm. Finally, we electroporated chicken
embryos with plasmids encoding GFP, Pdx1
WT, Pdx1
S61A or
Pdx1
S61E. The embryos were allowed to develop for 3 days, before
Figure 7. The Pdx1 NIA profile from in vivo b-cells is not unique and not responsive to glucose. To determine if the b-cells contain a
unique Pdx1 protein species we compared the NIA profiles of pancreata obtained from wild type mice and mice lacking the pro-endocrine gene
Neurog3. In the Neurog3
2/2 mice all b-cells are lost and the Pdx1 high expressing b-cells are no longer present. Thus, any modifications on Pdx1 that
are uniquely present in the b-cell should therefore only appear in the wild type profile. A and B) Immunohistochemical stainings of e15.5 Neurog3
+/+
or Neurog3
2/2 mouse pancreata, showing the distribution of Pdx1 (green) in the Chd1 positive endoderm (red). A’ and B’) the Pdx1 NIA analysis of
equivalent micro dissected tissue. Pdx1 NIA profile of pancreas tissue lysate from newborn (P2) (C) and adult NMRI mice (D). Results are representative
of two (Neurog3) or three independent (P2 and adult) experiments. E, F and G) Three independent purifications of islets from NMRI mice were
cultured for 2–3 days, washed with media lacking glucose, and then cultured with 2 mM glucose for two hours followed by incubation with 2 mM or
30 mM glucose for one hour E) Western blot on media from the islets, showing glucose responsiveness. F) Three preparations of mouse islets in
2 mM glucose. G) Three preparations of mouse islets in 30 mM glucose. H) Quantification of the three experiments showing the ratio of the pI 6.0
peak area under curve divided by the pI 6.1 peak area under curve. The error bars show standard deviation.
doi:10.1371/journal.pone.0035233.g007
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embryos were analyzed for the expression of GFP, Foxa2
(expressed in all endodermal cells) and Nkx6.1. Nkx6.1 is a
marker of pancreas development and has previously been shown
to be induced by Pdx1 [7,8]. In embryos electroporated with GFP
alone the pancreas and anterior endoderm developed normally
(Fig. 8E). Importantly, no expression of Nkx6.1 was detected in the
endoderm outside the pancreatic buds. When Pdx1
WT was
electroporated we observed a strong induction of ectopic Nkx6.1
expression in the endoderm anterior to the pancreas (Fig. 8F). To
investigate if the S61 phosphorylation has a role in pancreas
development we looked for ectopic activation of Nkx6.1 expression
Figure 8. Pdx1 is phosphorylated in the developing chicken endoderm but S61 phosphorylation is not required for ectopic
pancreas formation. Since the characteristic Pdx1 NIA profile was found early in mouse endoderm development (Fig. S3), we investigated the
function of Pdx1 by in ovo electroporation of plasmids encoding Pdx1 and GFP into the endoderm of developing chicken embryos. One day following
electroporation GFP expressing cells could be detected throughout the endoderm. A) OPT images showing the distribution of GFP expressing cells
(green). Following dissociation, the GFP expressing cells were purified using FACS. Before sorting, the GFP expressing cells constituted 0.3% of the
total number while the sorted fraction contained 53.5% GFP cells. B-D) The NIA profiles of the GFP positive fraction of embryos only electroporated
with GFP (B), GFP and Pdx1 in the GFP negative fraction from embryos electroporated with GFP and Pdx1 (C) and the GFP positive fraction from
embryos electroporated with both GFP and Pdx1 (D). In embryos electroporated with wild type Pdx1 the profile resembles the canonical Pdx1 profile.
E-H) 3D image projections of confocal sections obtained from chicken embryos stained for Nkx6.1 (red), GFP (green) and Foxa2 (blue) by whole
mount immunohistochemistry 72 hours after electroporation. In embryos electroporated with plasmids encoding GFP no ectopic Nkx6.1 expression
could be detected (E). In embryos electroporated with wild type Pdx1 we observed the induction of ectopic pancreata and associated Nkx6.1
expression (F; arrowheads). Plasmids encoding Pdx1
S61A (G) and Pdx1
S61E (H) and also induced ectopic pancreata when electroporated into the
endoderm. We also observed that the ectopic pancreata induced by wild type Pdx1 and S61A was associated with ectopic insulin expression (Fig. S4).
dp (dorsal pancreas), st (stomach). Results are representative for two independent FACS analyses and at least three wholemount stainings for each
Pdx1 construct.
doi:10.1371/journal.pone.0035233.g008
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S61A and Pdx1
S61E
(Fig. 8G, 8H). We found that both mutants induces pancreas
budding and Nkx6.1 expression to exactly the same extent as the
wildtype and it is therefore unlikely that phosphorylation of S61
has a role in pancreas development. In embryos electroporated
with Pdx1
WT the ectopic Nkx6.1 was found scattered within the
Foxa2 positive endoderm. However, in several cases we observed
that the Nkx6.1 cells became organized into a branched
epithelium very similar to the endogenous pancreas (arrows in
Fig. 8F-8H). We therefore speculated that the ectopic Nkx6.1
expression might actually reflect the formation of ectopic
pancreata. To test this we stained embryos electroporated with
Pdx1
WT or Pdx
1S61A for GFP, Nkx6.1 and insulin. In all embryos
where we could detect ectopic Nkx6.1 expression anterior to the
pancreas we also observed insulin expression (Fig. S4A and S4B).
Discussion
One advantage of the NIA technology is that one antibody is
used for the detection of all protein species which can be separated
by electrical charge. In recent years NIA has been used
successfully to study signal transduction [41,42] but, to the best
of our knowledge this work represents the first study where the
technology has been applied to a transcription factor. When
analyzing the profile of the homeobox containing transcription
factor Pdx1 we find at least four differently charged protein species
Pdx1
6.
0, Pdx1
6.
1, Pdx1
6.
3 and Pdx1
6.
4. These data were obtained
using two different antibodies against Pdx1 and we were able to
shift the peaks by adding an epitope tag. Furthermore, the four
peaks are always present when Pdx1 is expressed in eukaryotic
cells (bTC, mouse islets, mouse embryonic pancreas, L cells,
HEK293, aTC and chicken endoderm cells) while bacterially
derived Pdx1 only produces a single peak. Given the similar SDS-
PAGE mobility of eukaryotic and bacterial Pdx1 we conclude that
the NIA peaks we observe are due to post-translational
modifications. Also, as both eukaryotic and bacterially expressed
Pdx1 gives a single band using western blots we conclude that the
post-translational modifications must be relatively small, i.e. under
1000 Da.
One very important aim of this study was to determine the pI of
bacterially expressed and hereby minimally modified Pdx1 protein
and to this end confirm that the Pdx1 protein is in fact subjected to
post-translational modification in eukaryotic cells. We did this by
comparing the NIA profiles of Pdx1 purified from bacteria and
mammalian cells. As expected the bacterial protein produced a
single peak. However, the bacterial peak has a pI of 7.2 while the
predicted pI for unmodified mouse Pdx1 is 6.4. In lysates from
eukaryotic cells the most prominent peak actually runs at 6.4,
importantly when comparing bacterial and mammalian Pdx1 we
used exactly the same open reading frame for expression and we
sequence verified the different expression vectors and can
conclusively rule out any possibility of errors in the constructs or
the presence of alternative start sites. We therefore conclude that
the pI for unmodified Pdx1 is pI 7.2 and that it is a coincidence
that the 6.4 peak observed in eukaryotic cells has the same pI as
predicted for unmodified Pdx1. This is supported by NIA analysis
of human pdx1, which has a predicted pI of 7.1, but when over
expressed in HEK293 cells gives the dominant peak at pI 6.6 (data
not shown). Interestingly, on western blots Pdx1 also behaves
differently from what would be expected. The predicted molecular
weight of Pdx1 is 31 kDa but on gels the protein migrates at 40–
46 kDa. This difference has now been proven by mass
spectrometry to be due to anomalous SDS-PAGE mobility of
the pdx1 protein [45] and we speculate that similar anomalous
properties of Pdx1 in isoelectric focusing is the reason for the
difference between observed and predicted pI of bacterially
expressed Pdx1 protein.
Using the NIA assay and mass spectrometry we identified S61
as the primary phosphorylation and that the modification is
responsible for the 6.0 peak. However, the mass spectrometry also
identified phosphorylations on Y140/T141, S269 and in the NIA
profile we could still detect a smaller peak at 6.0 in the S61A
mutant that could be shifted following de-phosphorylation. To test
if Y140/T141 orS269 could account for the residual phosphor-
ylation in Pdx1
S61A we generated the following double mutants
Pdx1
S61A/Y140A, Pdx1
S61A/T141A Pdx1
S61A/S269A. However, all the
double mutants showed low levels of phosphorylation (data not
shown). Given the numerous publications describing other
phosphorylation sites on Pdx1 it is obvious that any of those
could be present together with the S61 phosphorylation.
Given the dynamic and often fast exchange of phosphorylation
and post-translational modifications in general it is remarkable
that there is so little variation between Pdx1 obtained from the
very different cell types. Both endogenous and ectopically derived
Pdx1 produces profiles where the 6.0 and 6.4 peaks represent the
predominant protein species. Subtle variations might be found, for
example the 6.1 peak appears to be more abundant in the E15.5
embryonic tissue. However, only in isolated islets do we observe a
significantly different peak at pI 6.9. This peak is interesting for
several reasons. First, it is only observed following treatment with
8 M urea indicating that in HNG buffer this Pdx1 species is
masked from antibody detection. A likely explanation is that that
the 6.9 species only exists in a tight protein-protein complex.
Second, the 6.9 peak is only found in isolated islets strongly
suggesting that it is unique to mature beta-cells. It should be noted
that that the 6.9 peak, was absent in post-natal and adult pancreas,
but this is probably due to the expression of Pdx1 in acinar cells,
masking the Pdx1 signal from the relatively few b-cells present in
the adult mouse pancreas [46].
What our data clearly shows is that the level of glucose has no
impact the NIA profile of Pdx1 from purified mouse islets. This is
in agreement with other studies also using non-invasive detection
techniques to study Pdx1 protein from both mouse, human and rat
islets [29,45]. One explanation for this could be that the factors
modifying Pdx1 are ubiquitous. For example if the posttransla-
tional modifications of Pdx1 were coupled to common events such
as the cell cycle [47]. Alternatively, ubiquitous factors known to
interact with Pdx1 such as p300 [48] might be present in all cell
types and therefore influence the profile in a similar manner.
One important feature of the NIA assay is that can be used to
study how the different modifications influence each other.
Although we fail to identify the modification responsible for the
6.3 and 6.4 peaks it is very obvious that these peaks are uncoupled
from the phosphorylation of S61. Thus the de-phosphorylation
only affects the 6.0 and 6.1 peaks. Furthermore, S61E which
mimics a constitutive phosphorylation abolished other protein
isoforms. One explanation for this could be that the modification
responsible for the 6.3/6.4 peaks only can occur when S61 is not
phosphorylated.
Likewise the residual phosphorylation peak (6.0) in Pdx1
S61A is
remarkably larger than what would be expected if the secondary
phosphorylation peak (5.9) of the wild type Pdx1 protein was
shifted to (6.0). Thus interactions between different modifications
or redundant phosphorylation sites are likely to influence the
dynamics of Pdx1 modification.
In conclusion, we show that Pdx1 harbors several post-
translational modifications and that phosphorylation of serine 61
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regulated by glucose in mouse islets.
Materials and Methods
Nanofluidic Proteomic Immunoassay (NIA)
This assay, here designated NIA, was developed by Cell
Bioscience[42].AllrunsweredoneontheNanopro1000instrument
andperformedessentiallyasdescribedbythemanufacturer(http://
www.cellbiosciences.com/nanopro.html). The NIA assay is a fully
automated, nanocapillary-based immunoassay based on isoelectric
focusing (IEF) to separate the proteins in a regular cell or tissue
lysate. Following separation the proteins are linked to the capillary
wall through UV irradiation and then probed with primary and
secondary antibodies. The secondary antibody is HRP-labeled,
which enables sensitive chemiluminescence detection. The signal,
which is black dots equivalent to that obtained by western blotting
are then analyzed by special software and can be viewed as either a
graph or a virtual gel. All NIA data presented in this study were
obtainedbyduplicateanalysisofthedescribedlysatesineitherHNG
buffer (20 mM Hepes, pH7.5, 25 mM NaCl, 10% glycerol) or 8 M
urea, both supplemented with 20 mM DTT. This was done to
compare the NIA profile under conditions of semi- and full-
denaturation. Samples were then mixed 1:1 with a sorbitol based
premix,containingfivepeptidestandardswithknownpI(pIladder1
cat.no. 040–644). The same premix was used for all runs and it
enables the generation of a pH gradient ranging from 4 to 9 (cat.no.
040–319). To establish the pH gradient, the anolyte were 10 mM
phosphoricacidandthecatholytewere100 mMsodiumhydroxide.
The proteins were focused for 40 min. at 15 mW, and then
incubated for 2 hours with primary antibody; 4 times wash with
TBST and 1 hour with the secondary HRP conjugated antibody,
washed again and lastly, chemiluminescence detection with Super-
Signal West Dura from Pirece. Concerning peak identification we
observe small variations from run to run. The peak at pI 6.40 could
therefore vary from 6.36 to 6.44. However, the relative distance
between peaks in the same run was always the same.
Dephosphorylation was done in vitro using Lambda phosphatase
(NEB, Cat.no. P0753). Cell lysate were diluted 10 times in reaction
buffer (50 mM HEPES, 100 mM NaCl, 2 mM DTT, 4 mM
MnCl2), split in two and treated with 1 ml (400 units) lambda
phosphatase or 1 ml water for 30 min. at 37uC. Afterwards the
reactions were diluted once in HNG or 8 M urea, both with
20 mM DTT and analyzed by NIA as described above.
MS Analysis
All MS experiments were performed on a nanoscale HPLC
system (EASY-nLC from Proxeon Biosystems) connected to a
hybrid LTQ–Orbitrap Velos (Thermo Fisher Scientific) equipped
with a nanoelectrospray source (Proxeon Biosystems). Each
peptide sample was auto-sampled and separated in a 15 cm
analytical column (75 mm inner diameter) in-house packed with 3-
mm C18 beads (Reprosil Pur-AQ, Dr. Maisch) with a 2 h gradient
from 5% to 40% acetonitrile in 0.5% acetic acid. The MS
instrument was operated in data-dependent mode to automatically
switch between full-scan MS and MS/MS acquisition. Survey full-
scan MS spectra (from m/z 300–1,700) were acquired in the
orbitrap with resolution R = 30,000 at m/z 400 (after
accumulation to a ‘target value’ of 1,000,000 in the linear ion
trap) using a HCD top10 method. The ten most intense peptide
ions with charge states $2 were sequentially isolated to a target
value of 50,000 using predictive automatic gain control (pAGC)
and fragmented by higher-energy collisional dissociation (HCD) in
the octopole collision cell using normalized collision energy of
40%. The ion selection threshold was 5,000 counts for HCD and
the maximum allowed ion accumulation times were 500 ms for
full scans and 250 ms for HCD. All HCD fragment ion spectra
were recorded in the orbitrap with a resolution of 7,500 at m/
z 400. For all full scan measurements a lock-mass ion from
ambient air (m/z 445.120025) was used for internal calibration
when present, as described [49]. Standard mass spectrometric
conditions for all experiments were: spray voltage, 2.2 kV; no
sheath and auxiliary gas flow; heated capillary temperature,
200uC; predictive AGC with calibrated scaling factor of about
100, and an S-lens RF level of 60%.
Identification of Peptides and Proteins by MaxQuant
The data analysis was performed with the MaxQuant software
(version 1.0.14.7, www.maxquant.org) as described [50] supported
by Mascot (www.matrixscience.com) as the database search engine
for peptide identifications. We followed the step-by-step protocol
of the MaxQuant software suite [51] to generate MS/MS peak
lists that were filtered to contain at most six peaks per 100 Da
interval and searched by Mascot (Version 2.2.04) against a
concatenated target/decoy (forward and reversed) version of the
IPI human database version 3.37 (69.316 forward protein entries).
Protein sequences of common contaminants such as human
keratins and proteases used were added to the database. The initial
mass tolerance in MS mode was set to 7 p.p.m. and MS/MS mass
tolerance was 0.02 Da. Cysteine carbamidomethylation was
searched as a fixed modification, whereas lysine acetylation,
serine/threonine/tyrosine phosphorylation, protein N-acetylation,
and oxidized methionine were searched as variable modifications.
A maximum of two mis-cleavages was allowed while we required
strict tryptic specificity. The resulting Mascot.dat files were loaded
into the MaxQuant software together with the raw data for further
analysis. To minimize false identifications, all top-scoring peptide
assignments made by Mascot were filtered based on previous
knowledge of individual peptide mass error. Peptide assignments
were statistically evaluated in a Bayesian model on the basis of
sequence length and Mascot score. We accepted peptides and
proteins with a false discovery rate of less than 1%, estimated on
the basis of the number of accepted reverse hits.
Chicken Electroporations and FACS Analysis
Chicken electroporations was performed as previously described
[44]. Wholemount immunefluorescence staining on mouse and
chicken embryos were performed as previously described [52]. For
OPT analysis embryos were stained and scanned on an OPT
scanner 3001 M (Bioptonics, Edinburgh UK) according to
manufacturers instructions. For FACS all embryos were electro-
porated with 10 mg of pCGIG5 vector containing the gene for
cytoplasmic EGFP as well as 10 mg of either empty vector or
mouse Pdx1
WT. The embryos were harvested 24 hours after
electroporation by digestion with 300 ml 1% trypsin per 2 embryos
for 10 min. at 37uC, with 3 rounds of gentle pipeting. The trypsin
were neutralised with DMEM media containing 10% FBS. After
centrifugation at 12006g for 5 min. the cells from 12 embryos
were resuspended in app. 7 ml FACSflow buffer and sorted by
EGFP fluorescence on a FACSaria instrument (BD Bioscience).
The resulting fractions were either EGFP negative, app.
1.5 million cells or EGFP positive, app. 50.000 cells. These
fractions were centrifuged and the EGFP negative fractions lysed
in 100 ml lysis buffer and the EGFP positive fractions in 4 ml. For
details on the lysis buffer please refer to the supplementary
information.
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bTC3 (bTC), aTC1.3 (aTC), L and HEK293F (HEK293) cells
were cultured in DMEM with 10% FBS and 1% pen/strep. bTC,
L and HEK293 cells were cultured with 5 g/L glucose, and aTC
with 1g/L glucose. Islets from wild type NMRI mice were isolated
using collagenase digestion and were grown for 5 days in RPMI
1640 with 10%FBS and 1% pen/strep. All embryonic mouse
tissue were from wild type NMRI mice, expect for the Neurog3-
knockout [53]. For analysis of embryonic pancreas tissue time-
mated mice were sacrificed at the indicated gestational stage, the
embryos were removed and the embryonic pancreas dissected
under microscope using a small knife and forceps.
Cloning and Plasmids
Wildtype mouse Pdx1 (Pdx1
WT) cDNA were obtained as an
imageclone from Open Biosystems (GenBank: BC103581.1). This
cDNA was amplified by PCR and inserted in the pENTR/D
vector (Invitrogen) and then transferred to our previously
published expression vector pCGIG5 [44], for expression in
eukaryotes and to the pEXP2 plasmid (Invitrogen) for expression
in bacteria. To generate, the 3xFlag version we used a 3’ primer
comprising the tag. To introduce point mutations we performed
chimeric PCR using primers covering 12 nucleotides up and down
stream of the codon being modified. Correct clones were identified
by diagnostic RE digests and sequence verified (MWG, Ebersberg,
Germany). As control we used the pCGIG5 vector either without
insert (designated empty vector) or with EGFP. Wildtype GSK3b
were cloned from Xenopus and a kind gift from Chris Wright.
Cell/tissue Harvest
For direct NIA and western analyzes all cell lines, tissue and
islets were lysed in Tissue Extraction Reagent I (50 mM Tris,
pH 7.4, 250 mM NaCl, 5 mM EDTA, 2 mM, Na3VO4,1m M
NaF, 20 mM Na4P2O7, 0.02%NaN3, and proprietary detergent),
from Invitrogen. Prior to use this buffer was supplemented with
protease inhibitors (Complete protease inhibitor cocktail tablets,
Roche). Before harvest, the cells were washed once in PBS and
thoroughly aspirated. One 6-well of cells was lysed in app. 100 ml,
one litter of E15.5 pancreata was lysed in 20 ml and 200 islets in
8 ml. For the Neurog3-KO, individual pancreata were isolated and
snap-frozen in dry ice and kept at 280uC, while genotyping was
performed. Pancreata with the three different genotypes was
pooled and lysed in 5 ml buffer per four pancreata. HEK293
lysates for immunoprecipitation followed by NIA, western or mass
spectrometry analysis were harvested as nuclear extracts; One
15 cm dish were washed once in PBS followed by cytolysis for
10 min. in 1.5 ml buffer A (10 mM HEPES pH 7.9, 10 mM KCl,
0.1 mM EDTA and 0.4% Triton X-100, Complete protease
inhibitor cocktail tablets). Then, scraped and dissociated by
pippeting and centrifuged at 10.000xg for 5 min. The pellet was
resuspended in 300 ml buffer B (20 mM HEPES pH 7.9, 400 mM
NaCl, 2 mM EDTA and 20% glycerol, Complete protease
inhibitor cocktail tablets), sheared using a 21 G needle and shaken
for 1 hour at 4uC. To generate the bacterially expressed protein,
30 ml of BL21 overnight culture was added to 250 ml fresh media
and grown for 3 hours before induction with 1 mM IPTG for
additionally 6 hours. The resulting bacteria pellet was washed and
resuspended in 12 ml TBST supplemented with protease
inhibitors, followed by sonication on ice.
Additionally, all lysates were kept on ice for at least 10 min, with
2 rounds of vortexing, followed by centrifugation at 16.0006g for
20 min. and then transferred to clean tubes and kept at 280uC.
Immunoprecipitation (IP) and Western Blotting (WB)
For IP of wildtype Pdx1, BL21 lysates and nuclear extracts from
HEK293 cells transfected with empty vector or Pdx1
WT were
incubated with 5 mg mouse-a-Pdx1 antibody and 50 ml magnetic
protein G dynabeads (Invitrogen) per ml of lysate, for 3 hours at
4uC with end-over turning. Following four washes in TBST the
beads were eluted in 8 M urea supplemented with 20 mM DTT at
30uC for 60 min with shaking. For IP of 3xFlag tagged Pdx1,
BL21 lysates and nuclear extracts from HEK293 cells transfected
with empty vector or Pdx1
3xFLAG were incubated with 25 ml
magnetic a-Flag beads (Sigma) per ml of lysate for 3 hours at 4uC
with end-over turning. Following four washes in TBST the 25 ml
beads were eluted with 125 ml of 100 mg/ml 3xFlag peptide in TBS
at 37uC for 60 min with shaking. Lastly, all eluates were
concentrated app. 20 fold using spin columns with a 10 K cut-
off (Amicon).
Pdx1 protein for mass spectrometry was prepared from nuclear
extracts of HEK293 cells transfected with Pdx1
WT and immuno-
precipitated as described above, however elution from the beads
were done by heating at 80uC with LDS sample buffer (Invitrogen)
containing 20 mM DTT. Following SDS-PAGE, the gel was
stained with Coomassie (Imperial stain, Pierce); the band of
interest cut out, destained with ammonium sulphate and sliced
into small pieces; then reduced with DTT and alkylated using
chloroacetamide. Finally, the proteins were digested overnight
with trypsin, loaded onto StageTips and subjected to mass
spectrometric analysis.
Western blots were done using precast NuPAGE Novex Bis-Tris
gels and blotted onto PVDF membranes (Invitrogen). All
membranes were stained with Ponceau S to verify uniform
blotting. Destaining was done with 5% acetic acid. Blocking and
antibody diluent were 5% skim milk with 0.1% tween-20. The
antibodies were applied for 1 hour at room temp or overnight at
4uC. Detection was done with Supersignal west pico from Pierce.
Afterwards, when appropriate the membranes were incubated
overnight in skim milk with 0.02% sodium azide and then
reproped with another primary antibody of a different species.
Cell line Transfections
For transfection of aTC and L cells, plasmid DNA was purified
from 40 ml overnight TOP10 bacteria culture using the S.N.A.P.
kit from invitrogen. All pointmutants were transfected into each
cell line in at least two different cell passages. This was done in 6-
or 12-well plates using Lipofectamine2000 according to manufac-
tures instructions. For transfection of HEK293 cells, plasmid DNA
was isolated from 600 ml overnight culture using the Megaprep
kit, from Invitrogen. HEK293 cells were transfected with empty
vector or Pdx1
WT in 15 cm dishes using Lipofectamine2000
according to manufactures instructions.
Antibodies
Primary goat-a-Pdx1 was a kind gift from Chris Wright and
used at 1:50.000 for western, 1:10.000 for immunofluorescence
and between 1:50 and 1:500 for NIA. Primary mouse- a-Pdx1
from the Hybridoma bank (1 mg/ml) was used at 1:10.000 for
western, 1:5–1:50 for NIA and for IP at 5 mg/ml lysate. Rabbit-
a-GFP from Invitrogen were used for NIA at 1:50 and mouse-a-
Hsp70 from Abcam was used for NIA at 1:1.000. For western,
mouse-a-b-Actin from Sigma was used at 1:25.000, guine a pig-
a-insulin from Abcam at 1:100 and mouse-a-GSK3a/b from
R&D at 1:500. For immunofluorescence; rabbit-a-GFP from
Clonetech was used at 1:500, mouse-a-Nkx6.1 from the
Hybridoma bank at 1:1000 and goat-a-FoxA2 from Santa Cruz
at 1:250. All secondary antibodies were from Jackson Immunor-
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were HRP conjugated and used at 1:10.000 (western) or 1:500
(NIA). For immunofluorescence they were Cy2, Cy3 or Cy5
conjugated and used at 1:300.
Supporting Information
Figure S1 Spiking of Pdx1
3xFLAG purified from bacteria
into HEK293 cells expressing either EGFP
Flag or
Pdx1
3xFlag. To further validate that the pI of bacterially expressed
Pdx1doesdifferfromthatofPdx1expressedinthehumanHEK293
cell line, we mixed the purified Pdx1
3xFLAG protein sample from
BL21 bacteria into HEK293 lysate expressing either EGFP
FLAG or
Pdx1
3xFLAG and then ran the NIA assay. As control we spiked
HEK293 lysates expressing (A) EGFP
FLAG or (B) HEK293 lysates
expressing Pdx1
3xFLAG with a negative control sample consisting of
bacterial proteins purified from untransformed bacteria. As
expected from Fig.3 we only observed the Pdx1
3xFLAG profile. (C
and D) Then we spiked the same two HEK293 lysates with purified
bacterially expressed Pdx1
3xFLAG and it is clear that the profile was
not altered by mixing the samples before doing the NIA analysis.
Two analyses were performed giving similar results.
(TIF)
Figure S2 NIA profile of endogenous Pdx1 using the
mouse-a-antibody. Samples were diluted in 8 M urea and
analyzed by NIA with the mouse-a-Pdx1 antibody. This was done
in parallel to the profiles obtained with the goat-a-Pdx1 antibody,
presented in figure 3. A-D) NIA analysis showing the profile of
bTC (A), aTC (B), E15.5 pancreas (C) and islets (D) obtained with
the mouse-a-Pdx1 antibody (red) superimposed on the profile
obtained from the same samples using the goat-a-Pdx1 antibody
(grey). Two analyses were performed giving similar results.
(TIF)
Figure S3 The Pdx1 protein is detected in developing
mouse endoderm. Immunohistochemical stainings showing the
Pdx1 expression (green) in the Chd1 positive endoderm (red). At
e10.5 (A) and e12.5 (B) Pdx1 is expressed uniformly in the
pancreas, posterior stomach and in the duodenum. A’ and B’)
Pdx1 NIA analysis of equivalent micro dissected tissue, showing
that during very early development at e10.5 Pdx1 also appears to
show the characteristic NIA profile and two days later at e12.5 the
profile is easily recognizable. Results are representative of three
independent experiments.
(TIF)
Figure S4 Both Pdx1
WT and Pdx1
S61A induces ectopic
insulin expression in vivo. 3D image projections of confocal
sections obtained from chicken embryos stained for Insulin (red),
Nkx6.1 (blue) and GFP (green) by whole mount immunohisto-
chemistry 72 hours after electroporation. In embryos electropo-
rated with plasmids encoding (A) Pdx1
WT or (B) Pdx1
S61A we
observe an equal amount of ectopic insulin production. Two
analyses were performed giving similar results.
(TIF)
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